References
- Keating M.J., Kantarjian H., Talpaz M., et al. Flu-darabine: a new agent with major activity against chronic lym-phocytic leukemia. Blood 1989; 74: 19–25
- Hiddemann W., Rottmann R., Wormann B., et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase II study. Ann. Hematol. 1991; 63: 1–4
- Keating M.J., Kantarjian H., O'Brien S., et al. Flu-darabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
- Zinzani P.L., Lauria F., Rondelli D., et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur. J. Hematol. 1993, (in press)
- Dow L.W., Bell D.E., Poulakos L., et al. Differences in metabolism and cytotoxicity between 9-β-D-arabino-furanosyladenine and 9-β-D-arabinosyl-2-fluoroadenine in human leukemic lymphoblasts. Cancer Res. 1980; 40: 1405–1410
- Brockman R.W., Schabel F.M., Jr., Montgomery J.A. Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofurano-syl-adenine. Biochem. Pharmacol. 1977; 26: 2193–2196
- Kerr J. F. R., Wyllie A.H., Currie A.R. Apop-tosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972; 26: 239–257
- Alley M.C., Scudiero D.A., Monks A., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48: 589–592
- Zinzani P.L., Clark J.W., Kouttab N.M., et al. Lymphokine-activated killer (LAK) activity using XTT-micro-culture tetrazolium assay against the melanoma MELTANG cell line. Immunity to Cancer. SBT, Williamsburg. November 16–19, 1989; 14, (abstract N. 36)